Normal and malignant choroidal melanocytes: From cell to clinical approach;Les mélanocytes choroïdiens normaux et malins: De la cellule à la clinique

Journal Francais d'Ophtalmologie

Volumn 28, Issue 7, 2005, Pages 781-793

  Mouriaux, F ^a,b,d   Saule, S ^c   Desjardins, L ^c   Mascarelli, F ^b  

^a CHU CÔTE DE NACRE   (France)

^b INSERM   (France)

^c INSTITUT CURIE   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Cell biology; Choroidal; Melanocyte; Melanoma; Pathology; Proliferation; Protein

Indexed keywords

CANCER CELL; CANCER GROWTH; CELL MATURATION; CELL PROLIFERATION; CHOROID; CHOROID MELANOMA; COMPARATIVE STUDY; HUMAN; INTRAOCULAR TUMOR; MELANOCYTE; NEURAL CREST; PATHOLOGY; REVIEW; SKIN; UVEA; UVEA DISEASE;

EID: 26944479644     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(05)80996-9     Document Type: Review

References (85)

1. Boissy RE. Extracutaneous melanocytes. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP, editors. The pigmentary System. Physiology and Pathophysiology. New York: Oxford University Press; 1998. p. 59-73.
2. Hearing VJ, Tsukamoto K. Enzymatic control of pigmentation in mammals. Faseb J, 1991;5:2902-9.
3. Sahm M, Loeffler KU, Seifert P, Spitznas M. Effect of ultraviolet radiation on melanogenesis in four different types of cultured bovine ocular pigmented cells. Graefes Arch Clin Exp Ophthalmol, 2001;239:302-9.
4. Vidal JL, Bacin F, Albuisson E, Rozan R, Desjardins L, D'Hermies F, et al. Melanome 92. Étude épidémiologique des mélanomes uvéaux en France. J Fr Ophtalmol, 1995;18:520-8.
5. Le Douarin NM, Dupin E, Baroffio A, Dulac C. New insights into the development of neural crest derivatives. Int Rev Cytol, 1992;138:269-314.
6. Murphy M, Bartlett PF. Molecular regulation of neural crest development. Mol Neurobiol, 1993;7:111-35.
7. Riley PA. Radicals in melanin biochemistry. Ann N Y Acad Sci, 1988;551:111-9.
8. Borovansky J, Mirejovsky P, Riley PA. Possible relationship between abnormal melanosome structure and cytotoxic phenomena in malignant melanoma. Neoplasma, 1991;38:393-400.
9. Hach P, Borovansky J, Vedralova E. Melanosome-a sophisticated organelle. Sb Lek, 1993;94:113-23.
10. Harbour JW, Brantley MA, Jr., Hollingsworth H, Gordon M. Association between choroidal pigmentation and posterior uveal melanoma in a white population. Br J Ophthalmol, 2004;88:39-43.
11. Shibahara S, Tomita Y, Sakakura T, Nager C, Chaudhuri B, Muller R. Cloning and expression of cDNA encoding mouse tyrosinase. Nucleic Acids Res, 1986;14:2413-27.
12. Jackson IJ, Chambers DM, Tsukamoto K, Copeland NG, Gilbert DJ, Jenkins NA, et al. A second tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus. Embo J, 1992;11:527-35.
13. Pak BJ, Lee J, Thai BL, Fuchs SY, Shaked Y, Ronai Z, et al. Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene, 2004;23:30-8.
14. Shibahara S, Yasumoto K, Amae S, Udono T, Watanabe K, Saito H, et al. Regulation of pigment cell-specific gene expression by MITF. Pigment Cell Res, 2000;13:98-102.
15. Mouriaux F, Vincent S, Kherrouche Z, Maurage CA, Planque N, Monte D, et al. Microphthalmia transcription factor analysis in posterior uveal melanomas. Exp Eye Res, 2003;76:653-61.
16. McHam ML, Fulton A. Albinism. Int Ophthalmol Clin, 1992;32:185-200.
17. Park S, Albert DM, Bolognia JL. Ocular manifestations of pigmentary disorders. Dermatol Clin, 1992;10:609-22.
18. Mouriaux F, Hamedani M, Hurbli T, Uteza Y, Oubaaz A, Morax S. Le syndrome de Waardenburg. J Fr Ophtalmol, 1999;22:799-809.
19. Spritz RA. Piebaldism, Waardenburg syndrome, and related disorders of melanocyte development. Semin Cutan Med Surg, 1997;16:15-23.
20. Tassabehji M, Newton VE, Liu XZ, Brady A, Donnai D, Krajewska-Walasek M, et al. The mutational spectrum in Waardenburg syndrome. Hum Mol Genet, 1995;4:2131-7.
21. Cable J, Jackson IJ, Steel KP. Mutations at the W locus affect survival of neural crest-derived melanocytes in the mouse. Mech Dev, 1995;50:139-50.
22. Dupin E, Le Douarin NM. Development of melanocyte precursors from the vertebrate neural crest. Oncogene, 2003;22:3016-23.
23. Opdecamp K, Nakayama A, Nguyen MT, Hodgkinson CA, Pavan WJ, Arnheiter H. Melanocyte development in vivo and in neural crest cell cultures: crucial dependence on the Mitf basic-helix-loop-helix-zipper transcription factor. Development, 1997;124:2377-86.
24. Gonder JR, Ezell PC, Shields JA, Augsburger JJ. Ocular melanocytosis. A study to determine the prevalence rate of ocular melanocytosis. Ophthalmology, 1982;89:950-2.
25. Shields JA, Shields CL, Naseripor M, Eagle RC, Miller J. Choroidal melanoma in a black patient with oculodermal melanocytosis. Retina, 2002;22:126-8.
26. Gonder JR, Shields JA, Albert DM, Augsburger JJ, Lavin PT. Uveal malignant melanoma associated with ocular and oculodermal melanocytosis. Ophthalmology, 1982;89:953-60.
27. Sumich P, Mitchell P, Wang JJ. Choroidal nevi in a white population: the Blue Mountains Eye Study. Arch Ophthalmol, 1998;116:645-50.
28. Negrier S, Pervers B, Bailly C, Beckendorf V, Cupissol D, Dore JF, et al. Cutaneous melanoma. Br J Cancer, 2001;84:81-5.
29. Ganley JP, Comstock GW. Benign nevi and malignant melanomas of the choroid. Am J Ophthalmol, 1973;76:19-25.
30. Foulds WS. Current options in the management of choroidal melanoma. Trans Ophthalmol Soc UK, 1983;103:28-34.
31. Mehta RR, Bratescu L, Graves JM, Shilkaitis A, Green A, Mehta RG, et al. In vitro transformation of human congenital nevus to malignant melanoma. Melanoma Res, 2002;12:27-33.
32. Giannotti B, Carli P. Facteurs de risque de mélanomes dans les populations méditerranéennes. Ann Dermatol Venereol, 2001;128:992-6.
33. Murray TG. Small choroidal melanoma. Arch Ophthalmol, 1997;115:1577-8.
34. Desjardins L, Lumbroso L, Levy C, Plancher C, Asselain B. Facteurs de risque pour la dégénérescence des naevi choroïdiens: étude rétrospective de 135 cas. J Fr Ophtalmol, 2001;24:610-6.
35. Shields GL, Shields JA, Kiratli H, De Potter P, Cater JR. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology, 1995;102:1351-61.
36. Zimmerman LE, McLean IW. The natural course of untreated uveal melanomas. Doc Ophthalmol, 1980;50:75-82.
37. Shields JA, Shields CL, Eagle RC, Jr., Santos C, Singh AD. Malignant melanoma arising from a large uveal melanocytoma in a patient with oculodermal melanocytosis. Arch Ophthalmol, 2000;118:990-3.
38. Barr CC, Zimmerman LE, Curtin VT, Font RL. Bilateral diffuse melanocytic uveal tumors associated with systemic malignant neoplasms. A recently recognized syndrome. Arch Ophthalmol, 1982;100:249-55.
39. De Potter P. Ocular manifestations of cancer. Curr Opin Ophthalmol, 1998;9:100-4.
40. Gass JD, Gieser RG, Wilkinson CP, Beahm DE, Pautler SE. Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma. Arch Ophthalmol, 1990;108:527-33.
41. Borruat FX, Othenin-Girard P, Uffer S, Othenin-Girard B, Regli F, Hurlimann J. Natural history of diffuse uveal melanocytic proliferation. Case report. Ophthalmology, 1992;99:1698-704.
42. Mouriaux F, Chahud F, Maurage CA, Malecaze F, Labalette P. Implication of stem cell factor in the proliferation of choroidal melanocytes. Exp Eye Res, 2001;73:151-7.
43. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol, 1988;32:239-51.
44. Kuo PK, Puliafito CA, Wang KM, Liu HS, Wu BF. Uveal melanoma in China. Int Ophthalmol Clin, 1982;22:57-71.
45. Margo CE, McLean IW. Malignant melanoma of the choroid and ciliary body in black patients. Arch Ophthalmol, 1984;102:77-9.
46. Tucker MA, Shields JA, Hartge P, Augsburger J, Hoover RN, Fraumeni JF, Jr. Sunlight exposure as risk factor for intraocular malignant melanoma. N Engl J Med, 1985;313:789-92.
47. Vajdic CM, Kricker A, Giblin M, McKenzie J, Aitken J, Giles GG, et al. Eye color and cutaneous nevi predict risk of ocular melanoma in Australia. Int J Cancer, 2001;92:906-12.
48. Schwartz LH, Ferrand R, Boelle PY, Maylin C, D'Hermies F, Virmont J. Lack of correlation between the location of choroidal melanoma and ultraviolet-radiation dose distribution. Radiat Res, 1997;147:451-6.
49. Guenel P, Laforest L, Cyr D, Fevotte J, Sabroe S, Dufour C, et al. Occupational risk factors, ultraviolet radiation, and ocular melanoma: a case-control study in France. Cancer Causes Control, 2001;12:451-9.
50. Dolin PJ, Johnson GJ. Solar ultraviolet radiation and ocular disease: a review of the epidemiological and experimental evidence. Ophthalmic Epidemiol, 1994;1:155-64.
51. Foster WJ, Fuller CE, Perry A, Harbour JW. Status of the NF1 tumor suppressor locus in uveal melanoma. Arch Ophthalmol, 2003;121:1311-5.
52. Houlston RS, Damato BE. Genetic predisposition to ocular melanoma. Eye, 1999;13:43-6.
53. Sinilnikova OM, Egan KM, Quinn JL, Boutrand L, Lenoir GM, Stoppa-Lyonnet D, et al. Germline brca2 sequence variants in patients with ocular melanoma. Int J Cancer, 1999;82:325-8.
54. Shields CL, Shields JA, Eagle RC, Jr., De Potter P, Menduke H. Uveal melanoma and pregnancy. A report of 16 cases. Ophthalmology, 1991;98:1667-73.
55. Abramson DH, Rodriguez-Sains RS, Rubman R. B-K mole syndrome. Cutaneous and ocular malignant melanoma. Arch Ophthalmol, 1980;98:1397-9.
56. Jackson IJ. A cDNA encoding tyrosinase-related protein maps to the brown locus in mouse. Proc Natl Acad Sci USA, 1988;85:4392-6.
57. Augsburger JJ, Gonder JR, Amsel J, Shields JA, Donoso LA. Growth rates and doubling times of posterior uveal melanomas. Ophthalmology, 1984;91:1709-15.
58. Irvine AR, Mannagh J, Arya DV. Change in cell type of human choroidal malignant melanoma in tissue culture. Am J Ophthalmol, 1975;80:417-24.
59. McLean IW, Foster WD, Zimmerman LE. Choroidal melanoma. Arch Ophthalmol, 1980;98:1298-303.
60. Seddon JM, Gragoudas ES, Egan KM, Glynn RJ, Howard S, Fante RG, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology, 1990;97:769-77.
61. Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer, 1993;71:2299-305.
62. Jensen OA. Malignent melanomas of the human uvea. Recent follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol [Copenh], 1970;48:1113-28.
63. McLean IW, Keefe KS, Burnier MN. Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology, 1997;104:777-80.
64. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res, 2001;11:255-63.
65. Bechrakis NE, Sehu KW, Lee WR, Damato BE, Foerster MH. Transformation of cell type in uveal melanomas: a quantitative histologic analysis. Arch Ophthalmol, 2000;118:1406-12.
66. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci, 2003;44:1008-11.
67. Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jockel KH, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res, 2003;63:2578-84.
68. Halaban R, Pomerantz SH, Marshall S, Lambert DT, Lerner AB. Regulation of tyrosinase in human melanocytes grown in culture. J Cell Biol, 1983;97:480-8.
69. Hu F, Teramura DJ, Mah K. Normal uveal melanocytes in culture. Pigment Cell Res, 1987;1:94-103.
70. Hu DN, McCormick SA, Ritch R, Pelton-Henrion K. Studies of human uveal melanocytes in vitro: isolation, purification and cultivation of human uveal melanocytes. Invest Ophthalmol Vis Sci, 1993;34:2210-9.
71. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta, 2003;1653:2B-40.
72. Mouriaux F, Casagrande F, Pillaire MJ, Manenti S, Malecaze F, Darbon JM. Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes. Invest Ophthalmol Vis Sci, 1998;39:876-84.
73. Mouriaux F, Maurage CA, Labalette P, Sablonniere B, Malecaze F, Darbon JM. Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors. Invest Ophthalmol Vis Sci, 2000;41:2837-43.
74. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem, 2003;278:42409-18.
75. Lefevre G, Calipel A, Mouriaux F, Hecquet C, Malecaze F, Mascarelli F. Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. Oncogene, 2003;22:8813-22.
76. Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel MB, et al. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest, 2003;83:1771-6.
77. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res, 1999;5:1007-14.
78. Kunisada T, Yamazaki H, Hayashi SI. Review: ligands for receptor tyrosine kinases expressed in the skin as environmental factors for melanocyte development. J Investig Dermatol Symp Proc, 2001;6:6-9.
79. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci, 2002;43:1-8.
80. Mouriaux F, Kherrouche Z, Maurage CA, Demailly FX, Labalette P, Saule S. Expression of the c-kit receptor in choroidal melanomas. Melanoma Res, 2003;13:161-6.
81. Pache M, Glatz K, Bosch D, Dirnhofer S, Mirlacher M, Simon R, et al. Sequence analysis and high-throughput immunohistochemical profiling of KIT [CD 117] expression in uveal melanoma using tissue microarrays. Virchows Arch, 2003;443:741-4.
82. Lefevre G, Glotin AL, Calipel A, Mouriaux F, Tran T, Kherrouche Z, et al. Roles of SCF/c-Kit and effects of Glivec/ STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem, 2004.
83. Zuidervaart W, van der Velden PA, Hurks MH, van Nieuwpoort FA, Out-Luiting CJ, Singh AD, et al. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer, 2003;89:1914-9.
84. van der Velden PA, Zuidervaart W, Hurks MH, Pavey S, Ksander BR, Krijgsman E, et al. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer, 2003;106:472-9.
85. Tschentscher F, Prescher G, Zeschnigk M, Horsthemke B, Lohmann DR. Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet, 2000;122:13-7.